Company Profile
Milestone Pharmaceuticals Inc. Stock Price, News & Catalysts
- Ticker:
- MIST
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada
Stock performance
1.10 USD (0.00%)
Close
Last updated: August 17, 2026
164M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, MIST was little changed and closed at $1.10. No new same-company headline was identified in the current news window.
Company overview
Self-Administered Cardiac Rescue Therapy
Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting.
CARDAMYST
CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm.
Atrial Fibrillation Expansion
The Phase 3 ReVeRA-301 study evaluates etripamil in atrial fibrillation with rapid ventricular rate. The program uses the same self-administered regimen approved for paroxysmal supraventricular tachycardia.
International Development
The European Medicines Agency is reviewing etripamil for paroxysmal supraventricular tachycardia under the proposed brand TACHYMIST.
Future catalysts
- Enrollment of the first patient in the Phase 3 ReVeRA-301 study of etripamil in atrial fibrillation with rapid ventricular rate.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Milestone Pharmaceuticals Inc. (MIST)?
Milestone Pharmaceuticals Inc. (MIST) most recently closed at 1.10 USD, a 0.00% move versus the previous session.
What is the market cap of Milestone Pharmaceuticals Inc. (MIST)?
Milestone Pharmaceuticals Inc. currently has a market capitalization of 164M USD on BioPharmSignal.
What does Milestone Pharmaceuticals Inc. do?
Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to...
On which exchange is MIST stock listed?
Milestone Pharmaceuticals Inc. (MIST) is associated with NASDAQ, Canada, Biopharma.
What is Self-Administered?
Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting.
Which conditions is Milestone Pharmaceuticals Inc. targeting with Self-Administered?
Milestone Pharmaceuticals Inc. is associated with cardiovascular disease based on its company overview and current catalyst commentary.
How does Milestone Pharmaceuticals Inc. describe recent progress with Self-Administered?
Enrollment of the first patient in the Phase 3 ReVeRA-301 study of etripamil in atrial fibrillation with rapid ventricular rate.
What is Cardiac?
Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting.